8-K Announcements
6Material company update
May 19, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Apr 13, 2026·SEC
Oragenics, Inc.(OGEN)Earnings, Financials & Key Ratios
OGEN•AMEX
$0.57
Price updated Jul 7, 2026
AboutOragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.Show more
- Revenue$0
- EBITDA-$9M+11.2%
- Net Income-$10M+6.9%
- EPS (Diluted)-4.56-185.0%
- ROE-243.94%+65.9%
OGEN Price & Volume
Oragenics, Inc. (OGEN) stock price & volume — 10-year historical chart
Loading chart...
Persistent Pre-Commercial Burn Threatens Capital Stability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
Key Thesis Takeaways
- Oragenics remains a high-risk, pre-commercial biotechnology entity that has failed to generate any revenue over the last ten quarters, leaving it entirely dependent on external financing.
- The company's reliance on R&D spending, which reached $645.5K in 2026Q1, continues to erode its equity base, which now faces a cumulative deficit of $228.8 million in retained earnings.
- Investors should monitor the narrowing cash runway, as the current $6.1 million cash position may necessitate further dilutive capital raises to sustain clinical development.
Verdict Logic
the company's precarious financial position is highlighted by a $228.8 million deficit in retained earnings and a reliance on external capital to fund ongoing R&D expenses.
OGEN Growth Metrics
Oragenics, Inc. (OGEN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM4.91%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-22.2%
Return on Capital
10 Years-201.94%
5 Years-269.22%
3 Years-400.8%
Last Year-232.05%
OGEN Recent Earnings
Oragenics, Inc. (OGEN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (83%)
Q2 2026Latest
May 8, 2026Metric
Actual
Est
EPS
$0.51+99.4%
$90.00
Rev
—
—
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.54+99.4%
$90.00
Rev
—
—
Q4 2025
Nov 7, 2025Metric
Actual
Est
EPS
$1.96
—
Rev
—
—
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$3.10
—
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $0.51vs $90.00+99.4% | — |
| Q1 2026 | Feb 26, 2026 | $0.54vs $90.00+99.4% | — |
| Q4 2025 | Nov 7, 2025 | $1.96 | — |
| Q3 2025 | Aug 8, 2025 | $3.10 | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Oragenics, Inc. (OGEN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.57 | $2.58M | -0.13 | — | — | -243.94% | — | |
| $3.67 | $263.23M | 11.12 | -31.8% | 21.61% | 10.62% | — | |
| $9.21 | $2.13B | 15.35 | 19.63% | 32.43% | 38.97% | — | |
| $9.46 | $1.56B | 3.72 | 64.69% | -14.73% | — | — | |
| $1.06 | $38.63M | -4.61 | -64.74% | -245.12% | -1004.96% | — | |
| $0.55 | $133.16M | 7.86 | 726.68% | 14.51% | 61.43% | — |
Compare OGEN vs Peers
Oragenics, Inc. (OGEN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OGEN SEC Filings & Documents
Oragenics, Inc. (OGEN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when OGEN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OGEN Frequently Asked Questions
Oragenics, Inc. (OGEN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is OGEN profitable?
Oragenics, Inc. (OGEN) reported a net loss of $9.8M for fiscal year 2025.
Dividend & Returns
What is OGEN's return on equity?
Oragenics, Inc. (OGEN) has a return on equity (ROE) of -243.9%. Negative ROE indicates the company is unprofitable.
What is Oragenics, Inc.'s free cash flow?
Oragenics, Inc. (OGEN) had negative free cash flow of $9.3M in fiscal year 2025, likely due to heavy capital investments.